Key Events This Week
05 Jan: New 52-week and all-time high at Rs.132.15
06 Jan: Fresh all-time high of Rs.138.75
07 Jan: Record high of Rs.144.4 reached
08-09 Jan: Price correction amid low volumes and Sensex decline
Mar 05
BSE+NSE Vol: 7.34 k

Checkpoint Trends Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by improved price-to-earnings and price-to-book value metrics. This change comes amid a challenging market backdrop where the stock has underperformed the Sensex in the short term but continues to deliver exceptional long-term returns, prompting a reassessment of its price attractiveness relative to peers in the Pharmaceuticals & Biotechnology sector.
Read full news article
Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 04 September 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 30 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.
Read full news articleCheckpoint Trends Ltd's latest financial results for Q3 FY26 present a complex picture characterized by significant revenue growth alongside notable profitability challenges. The company's net sales reached ₹174.09 crores, reflecting a sequential growth of 60.32% from the previous quarter, which is a substantial increase compared to the same period last year. This growth trajectory underscores the company's successful pivot from pharmaceutical manufacturing to trading operations, marking a remarkable year-on-year revenue increase of 173,990%. However, this revenue surge has not translated into improved profitability. The net profit for the quarter was ₹0.57 crores, representing a decline of 56.82% from the prior quarter's net profit of ₹1.32 crores. Additionally, the operating margin has contracted to 0.44%, down from 1.65% in Q2 FY26, indicating that the company is facing challenges in converting its sale...
Read full news article
Checkpoint Trends Limited (formerly Rubra Medicaments Ltd.), a micro-cap pharmaceutical company with a market capitalisation of ₹66.00 crores, reported a net profit of ₹0.57 crores for Q3 FY26, marking a decline of 56.82% quarter-on-quarter but a turnaround from losses recorded in the corresponding quarter last year. The company's stock, trading at ₹123.95, has surged 1089.54% over the past year, reflecting extraordinary investor enthusiasm despite fundamental concerns about profitability and business model sustainability.
Read full news articleThe next results date for Checkpoint Trends Ltd is scheduled for 28 January 2026....
Read full news article
Checkpoint Trends Ltd is rated 'Hold' by MarketsMOJO. This rating was last updated on 04 Sep 2025, reflecting a shift from a previous 'Sell' stance. However, the analysis and financial metrics discussed here represent the stock's current position as of 19 January 2026, providing investors with an up-to-date view of its performance and prospects.
Read full news article